Our latest paper is in press today PLOS Biology led by Abdallah Eteleeb & Oscar Harari on brain high-throughput multi- #omics & molecular heterogeneity in #Alzheimers . We found a multimodal profile with⬆️Braak tau, #synaptic , #endocytosis , #phagosome , & #mTOR pathways dx.plos.org/10.1371/journa…

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients w... sciencedirect.com/science/articl… Sharing our experience with a Quad in #mmsm Betsy O'Donnell Andrew Yee, MD Mass General Cancer Center

Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA Rx exposure, albeit with slightly poorer PFS; CD8 effector T cells enhance teclistamab response Ross Firestone Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Blood Advances #mmsm #bmtsm ashpublications.org/bloodadvances/…

Second myeloma CAR-T approval of the day!

Cilta-cel approved as second line therapy for MM. #mmsm businesswire.com/news/home/2024…

#Myeloma Paper of the Day: Nice review of tumor-intrinsic (loss of target antigen, MHC class I, preventing MHC class I:TCR co-stimulatory signaling) and -extrinsic resistance mechanisms (exhausted T cells & immunosuppressive TME) to T-cell engagers: pubmed.ncbi.nlm.nih.gov/38513088/.

woMMen of Myeloma's fundraising page for Multiple Myeloma Research Foundation give.themmrf.org/fundraiser/512…

ICYMI: frontiersin.org/journals/immun…

Idecel in renal impairment - from US MM consortium
haematologica.org/haematologica/…
Increased incidence of Gr 3 thrombocytopenia
PFS, CRS, ICANS rates similar
Practical management
-dose reduce Flu a/c to CrCl
-giving Flu/Cy after dialysis
-similar use of dex/toci for CRS/ICANS no dose…

US FDA approval of Q2W teclistamab in those who have achieved and sustained a CR for 6 months. #Myeloma #MyCompany

prnewswire.com/news-releases/…

Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation | Circulation ahajournals.org/doi/10.1161/CI…

#Myeloma Paper of the Day: Pre-clinical study of engineered T cells secreting anti-BCMA T cell engagers finds they control #myeloma and promote immune memory in vivo better than standard CAR T-cells: pubmed.ncbi.nlm.nih.gov/38354229/.

We've known for years that CD27 expression on manufactured CAR T cells correlates with clinical responses. Elegant work from the Riddell lab shows there's more to the story.

Ligating CD27 during CAR T manufacturing induces memory genes and boosts potency.
cell.com/immunity/fullt…

Now in Leukemia Journal: amazing #MMsm work by Fischer et al (senior author Merz) with ide-cel!

Same principle as with CD19... All CAR T-cells are created equal, but CD8s matter more!

And predestination at play? 'Cell composition at day of leukapheresis determines response.' 🤯

We are experiencing another spike of #COVID19 in the wastewater here in Mass; Biggest since late 21 early 22

🤩👏 A round of applause to Dr. Giada Bianchi's (Bianchi Lab) team on placing second in this year's countdown!

They uncovered 🧬 #mutations in the alternative complement pathway in multiple #myeloma patients with thrombotic microangiopathy!

twitter.com/Hema_News/stat…

Great, practical study presented at #ASH23 by Þórir Long from iStopMM that proposes a revised Binding Site free light chain ratio that is shifted up from 0.26-1.65 to e.g. 0.44-2.16 in patients <70 ash.confex.com/ash/2023/webpr…

Sonrotoclax for t(11;14) RRMM +dex. Ph1b/2. More potent? Low numbers but very interesting. Very safe and active. Time to defeat the t(11;14)!!
#ASH23RF #mmsm Susan Bal Amit Agarwal Binod Dhakal

Congratulations ⁦Bruno Paiva⁩ for this amazing data. CTCs is the way to go. #ash23 #mmsm

Dr Doris Hansen from Moffitt Cancer Center presenting her work on association of serum cytokines and pre-CAR-T bone marrow composition with toxicity and early response among patients with TCE RRMM treated with ide-cel.
#mmsm #ash23
ASH